Tengion is a young biotechnology company, which is located on the border of regenerative medicine, an emerging field that seeks to promote the creation of new cells and tissues to repair or replace tissue or organ function lost due to age, illness, injury, or congenital defects. In late 2008, Tengion management faced with a difficult dilemma. In light of the financial crisis, the company has the cash burn prioritizing its R & D efforts. Director General Nichtberger should recommend to the Council, which of the two promising new treatments to continue to grow when placed another call on hold. When comparing the two versions of a number of factors must be taken into account - is the range of estimates regulatory problems, the problems of production, marketing issues (eg, pricing), and partnership issues. Each of the treatments will highlight the unique patient population, which vary in size and composition. Tengion is also necessary to take into account how fast it can be expected to bring each of the two treatments on the market. The decision may have serious long-term consequences for the end of the survival and success. "Hide
by Elie Ofek, Polly Ross Ribatt Source: Harvard Business School 29 pages. Publication Date: October 30, 2009. Prod. #: 510031-PDF-ENG
Related Case Solutions & Analyses:
Stihl Incorporated: Go-to-Market Strategy for Next-Generation Consumers
Sony-FIFPartnership Marketing Program: The Value of Sponsorship
Kalashnikov: Whats in a Name (B)
Building a Social Media Culture at Dell
Law Assignment
Coke and Pepsi: from Global to Indian Advertising
HootSuite: Monetizing the Social Media Dashboard
Livelihood Advancement Business School
Strategic M&A Analysis
Cherries With Charm: Turkey’s Alara Agri
